Yunkang Group Limited Issues Positive Profit Alert: Signals Major Financial Turnaround for FY2025

Yunkang Group Limited (Stock Code: 2325), a leading healthcare service provider based in the PRC and listed on the Hong Kong Stock Exchange, has issued a Positive Profit Alert that may significantly impact investor sentiment and the company’s share value.

Key Highlights from the Report

• Expected Return to Profit: For the financial year ended December 31, 2025, Yunkang Group projects a net profit in the range of RMB 3.2 million to RMB 9.8 million. This marks a dramatic turnaround compared to a net loss of approximately RMB 793.2 million in the previous year (2024).
• Operational Improvements Amid Industry Challenges: The Group faced ongoing pressures from centralized procurement policies, medical insurance cost controls, and intensified industry competition. In response, Yunkang prioritized operational quality by:
  • Optimizing its customer mix and product portfolio
  • Deepening cooperation with medical institution alliances
  • Delivering more in-depth services to clients

  These measures have led to a stabilization in operational quality, with a gradual narrowing of revenue decline year-on-year.

• Cost Control and Efficiency Enhancement: Through lean operational measures, including strict cost control and precise resource allocation, the Group has achieved notable reductions in selling and administrative expenses. Additionally, an optimized debt structure has reduced finance costs.
• Improved Cash Flow and Receivables Collection: Yunkang has strengthened the management of cash and trade receivables, shortening the collection cycle and successfully recovering receivables from previous years. This has enabled the reversal of certain credit impairment losses, further supporting the financial turnaround.

Important Information for Shareholders

• Significant Turnaround: The shift from a substantial net loss to a projected net profit is a major development and could have a significant positive impact on the company’s share price.
• Revenue Trends: While overall revenue is expected to decline compared to last year, the pace of decline is slowing, and key segments such as diagnostic testing services for medical alliances are showing increasing strength.
• Ongoing Risk Factors: The Group remains exposed to market and policy risks, including continued pressure from government procurement and insurance policies as well as industry competition.
• Preliminary Figures: The profit estimates are based on draft unaudited management accounts. Final audited results will be published in March 2026, and figures may be subject to adjustment.
• Caution Advised: The Board explicitly advises investors and shareholders to exercise caution when trading in the company’s shares due to the preliminary nature of the financial data.

Leadership and Board Composition

The current Board comprises Mr. Zhang Yong (Chairman and Executive Director), Mr. Zhang Weijie, Dr. Wang Pinghui and Dr. Wang Ruihua (Non-executive Directors), and Mr. Yu Shiyou, Mr. Xie Shaohua, and Dr. Dong Min (Independent Non-executive Directors).

Outlook

Yunkang Group plans to maintain its focus on operational efficiency, cost control, and strengthening credit management going forward, aiming to further improve profitability and cash flow in the coming years.

Disclaimer: This article is based on preliminary unaudited figures provided by Yunkang Group Limited. Actual results may differ after audit review. Investors should exercise caution and refer to the official audited results announcement expected in March 2026 before making investment decisions. This material does not constitute investment advice.

View YUNKANG GROUP Historical chart here